Vogt-Koyanagi-Harada syndrome (review of case reports)
Tóm tắt
Vogt–Koyanagi–Harada (VKH) disease, also known as uveomeningitic syndrome, is a multisystem autoimmune disorder directed against any melanocyte-containing organ, including the eye, central nervous system, auditory, and integumentary system. We present a case of an African woman with total deafness and blindness of VKH, and discuss the histological characteristics, and review the classification and the management of VKH. The most important factor for prognosis is the immediate treatment. The rarity of this syndrome makes its diagnosis a challenge and the presence of deafness, tinnitus, and vertigo must be considered in its diagnosis.
Tài liệu tham khảo
Koyanagi Y. Dysakusis, Alopecia und Poliosis bei schwerer Uveitis nicht traumatischen Ursprugs. Klin Monatsbl Augenheilkd. 1929; 82: 194–211
Vogt A. Early graying of cilia and remarks about the genaten sudden Eintreitt of this change. Klin Monatsbl Augenheilkd. 1906; 44: 228–242
Harada E. Acute diffuse choroiditis. Acta Soc Ophthalmol Jpn. 1926; 30: 356–378
Ohno S, Minakawa R, Matsuda H. Clinical studies of Vogt-Koyanagi-Harada’s disease. Jpn J Ophthalmol. 1988; 32: 334–343
Rao NA. Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. Eye (Lond). 1997;11(Pt 2):213–216
Read RW, Rechodouni A, Butani N, Johnston R, LaBree LD, Smith RE, Rao NA. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001; 131: 599–606
Rao N, Blackman H, Franklin R, Meislar D, Sheppard J, Chalmers B, et al. VKH Syndrome, Panuvitis, Basic and Clinical Science Course, Sec 9. San Francisco: American Academy of Ophthalmology; 1998. pp. 130–133.
Hiraki Y, Kuwasaki N, Shoji H, Kaji M, Kuboshiro T. VKH syndrome with multiple cranial nerve palsies. Rinsho Shinkeigaku. 1981; 29: 54–58
Najman-Vainer J, Levinson RD, Graves MC, Nguyen B-T, Engstrom RE Jr., Holland GN. An association between Vogt-Koyanagi-Harada disease and Guillain-Barré syndrome. Am J Ophthalmol. 2001;131:615–619
Gruich MJ, Evans OB, Storey JM, Bradley ST, Chen CJ. Vogt-Koyanagi-Harada syndrome in a 4-year-old child. Pediatr Neurol. 1995; 13: 50–51
Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada’s disease by PCR-RFLP and the strong association with DRB1(*)0405 and DRB1(*)0410. Br J Ophthalmol. 1994; 78: 223–226
Islam SMM, Numaga J, Fujino Y, Hirata R, Matsuki K, Maeda H, Masuda K. HLA class II genes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994; 35: 3890–3896
Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000; 165: 7323–7329
Yamaki K, Gocho K, Sakuragi S. Pathogenesis of Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2002; 42: 13–23
Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001; 131: 647–652
Rubsamen PE, Gass JDM. Vogt-Koyanagi-Harada syndrome: clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991; 109: 682–687
Sasamoto Y, Ohno S, Matsuda H. Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease. Ophthalmologica. 1990; 201: 162–167
Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000; 130: 492–513
Rao NA. Management of intraocular inflammation. In: Ryan SJ, editor. Retina. Vol. 2 3rd ed. Philadelphia: Mosby; 2001.
Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006; 14: 87–90